Prognostic Factor for Prostate Cancer

Imai, Kyoichi; Suzuki, Takanori; Hayashi, Masamichi; Nakazawa, Yasuo; Nakata, S; Yamanaka, Hidetoshi; Kitaura, Koichi; Tomaru, Yukio; Miki, Masaya; Kato, Naoko; Sato, Jin; Takahashi, Hirotomo; Koya, Atsushi; Kuroda, Hiroshi; Minaguchi, Takeo; Ebihara, Kazunori; Shinozaki, Tadatoshi; Kurosawa, Isao; Matsushita, I; Takeuchi, Hiroyuki

doi:10.5980/jpnjurol1989.81.1217

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the above result indicates a better survival for subjects examined by M S, but not for the survival o f Pea patients detected by M S. Therefore, we analyzed the possibility o f a self-selection bias by evaluating the clinical data o f the Pea patients. We have reported that ESR in stage B and gait disturbance in all stages reflect the general condition o f patients with Pea [ 18]. In stage B and D patients there was a significant difference between M S and the controls (p < 0.05: tables 5, 6).…”

Section: Self-selection Biasmentioning

confidence: 83%

Mass Screening for Prostate Cancer and the Bias Relating to Survival Rate

Imai

Suzuki²,

Yamanaka³

et al. 1993

Urol Int

Self Cite

View full text Add to dashboard Cite

Since 1981 we have been studying prostate cancer (Pca) by mass screening (MS) in the Gunma Prefecture, Japan. From 1981 to 1990, 9,067 subjects (total 15,451) were examined in connection with this project and 121 subjects were diagnosed as having Pca. The presence of Pca in 87 cases was confirmed at their initial MS (initial group); 34 cases were confirmed either the year after or several years after the first MS (repeat group). To evaluate the significance of MS for Pca, in this group of patients, the effects of ‘lead time bias’, ‘self-selection bias’ and ‘length bias’ on the survival rate were compared to Pca patients detected in the hospitals of the Gunma Prefecture during the same period. The survival curves of MS cases for each stage of the disease were better than those of the controls. Only in stage D was there a significant difference between the two groups. However, this MS curve decreased from the 4th year in the same manner as the control curve from the start. The clinical characteristics (age, pathological differentiation, prostatic acid phosphatase, gait disturbance, erythrocyte sedimentation rate, chronic disease, and pain in the patients with stage D disease) were compared between both groups. All characteristics studied, except age, in the MS group were clinically more favorable compared to those of the controls for each stage or in total. Moreover, the relative survival rate of subjects examined by MS was greater than 1.0. No significant difference was found in stage distribution between the initial group and the repeat group. During the follow-up study, 15 Pca patients were found who had a history of MS examination but were diagnosed in standard hospitals. Only 2 of these 15 patients were diagnosed with Pea within 1 year following their last MS examination, and they had stage A disease. We conclude that MS should be performed annually and recommend that people who want an early diagnosis should receive MS once a year.

show abstract

Section: Self-selection Biasmentioning

confidence: 83%

Mass Screening for Prostate Cancer and the Bias Relating to Survival Rate

Imai

Suzuki²,

Yamanaka³

et al. 1993

Urol Int

Self Cite

View full text Add to dashboard Cite

show abstract

“…The latter was typified by having a more advanced stage distribution and (22) 3 (4) 8 (10) 12 (5) 20 (9) 12 ( younger mean age. These data suggest that the patients in the RPCI-2 group were self-or physicianreferred to RPCI because of the advanced nature of their disease or their younger age.…”

Section: Discussionmentioning

confidence: 99%

A Comparison of Prostate Cancer Patients in Japan and the Usa

et al. 1994

Self Cite

View full text Add to dashboard Cite

Clinical characteristics of prostate cancer patients were analyzed to compare the rates of progression of prostate cancer between patients in Japan (Gunma Urological Oncology Study Group: GUOSG) and the USA (Roswell Park Cancer Institute: RPCI), between 1980 and 1989. The stage of disease was more advanced and the age was greater in GUOSG patients compared with RPCI patients. However, the prostate cancer death rate of stage D patients at RPCI was significantly higher than that of the GUOSG. Moreover, the survival rate of stage A patients in the GUOSG was better than that of RPCI patients. The possibility of biases which may affect both the clinical characteristics and survival rates in the 2 populations studied is discussed. To determine whether there is a real difference in the rate of prostate cancer growth between the 2 countries will require a prospective study, ideally conducted in large population groups.

show abstract

“…Although chemical synthesis and enzymological studies are only tersely disclosed, a number of in vivo studies have been published. ONO rats (21,22). Clinical studies in humans are reportedly underway, although recent results are not available (23,24).…”

Section: Dihydrotestosterone (Dht)mentioning

confidence: 99%